Prick Test Histamin LETI Positivkontrolle 10 mg/ml Pricktestlösung

DRUG4 trials

Sponsors

ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH, Inmunotek S.L.

Conditions

Moderate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinebirch pollen-induced allergic rhinitis birch pollen-induced allergic rhinoconjunctivitis

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy

CompletedCTIS2023-505567-37-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22

Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy

CompletedCTIS2023-505880-35-00

ROXALL Medizin GmbH, ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy

CompletedCTIS2024-511383-88-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2024-09-01End: 2025-10-14Target: 50Updated: 2024-07-11

Phase 3

A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.

CompletedCTIS2024-515717-17-00

Inmunotek S.L.birch pollen-induced allergic rhinitis birch pollen-induced allergic rhinoconjunctivitis

Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07